{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:43:50Z","timestamp":1787928230926,"version":"build-2784847793"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Coagulation factor X (FX), originally named Stuart\u2013Prower factor, plays a pivotal role in the coagulation cascade, activating thrombin to promote platelet plug formation and prevent excess blood loss. Genetic variants in F10 may lead to FX deficiency and to impaired coagulation. FX variants are phenotypically classified as being type I, with the concomitant reduction of FX coagulant activity and FX antigen levels or type II, corresponding to a reduction in activity with normal antigen plasma levels. Patients affected with FX deficiency tend to be one of the most seriously affected among those with rare bleeding disorders. They show a variable bleeding tendency strongly associated with FX coagulant activity levels in plasma and may present, in the severe form of the deficiency, life-threatening symptoms such as gastrointestinal and umbilical stump bleeding and intracranial hemorrhages or central nervous system bleeding. Treatment of FX deficiency was originally based on the replacement of the missing factor using fresh frozen plasma, cryoprecipitate and prothrombin complex concentrates; however, a plasma-derived concentrate, shown to be safe and effective in clinical trials, is now available. In addition, novel nonreplacement therapy such as small interference RNA, gene therapy, drug repurposing, and gene editing may also represent novel therapeutic approaches for FX deficiency, but further, much focused studies are needed before considering this emerging therapy in such patients.<\/jats:p>","DOI":"10.1055\/s-0044-1789595","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T23:22:41Z","timestamp":1724973761000},"page":"138-144","source":"Crossref","is-referenced-by-count":6,"title":["Clinical, Laboratory Aspects and Management of Factor X Deficiency"],"prefix":"10.1055","volume":"51","author":[{"given":"Marzia","family":"Menegatti","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/07853890.2011.576698","article-title":"Inherited disorders of blood coagulation","volume":"44","author":"G Lippi","year":"2012","journal-title":"Ann Med"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11239-021-02456-w","article-title":"Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics","volume":"52","author":"R M Camire","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"102160","DOI":"10.1016\/j.rpth.2023.102160","article-title":"New insight into the traditional model of the coagulation cascade and its regulation: illustrated review of a three-dimensional view","volume":"7","author":"R Troisi","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjh.13058","article-title":"Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology","volume":"167","author":"A D Mumford","year":"2014","journal-title":"Br J Haematol"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1055\/s-0029-1225763","article-title":"Factor X deficiency","volume":"35","author":"M Menegatti","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41525-023-00375-8","article-title":"Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases","volume":"8","author":"O Seidizadeh","year":"2023","journal-title":"NPJ Genom Med"},{"issue":"08","key":"ref7","first-page":"373","article-title":"The nomenclature of blood clotting factors","volume":"86","author":"I S Wright","year":"1962","journal-title":"Can Med Assoc J"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"F Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/j.1538-7836.2012.04844.x","article-title":"Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity","volume":"10","author":"F Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1076029616686423","article-title":"Factor X Friuli coagulation disorder: almost 50 years later","volume":"24","author":"A Girolami","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2516.2006.01303.x","article-title":"Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene","volume":"12","author":"F H Herrmann","year":"2006","journal-title":"Haemophilia"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1046\/j.1365-2141.1998.00806.x","article-title":"Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients","volume":"102","author":"F Peyvandi","year":"1998","journal-title":"Br J Haematol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1046\/j.1365-2141.2002.03486.x","article-title":"Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency","volume":"117","author":"F Peyvandi","year":"2002","journal-title":"Br J Haematol"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/pbc.25966","article-title":"Intracranial hemorrhage as the first manifestation of severe congenital factor X deficiency in a 20-month-old male: case report and review of the literature","volume":"63","author":"T Diesch","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.jtha.2023.08.027","article-title":"Postmortem diagnosis of severe factor X deficiency in a fetus with intracranial hemorrhage resulting in intrauterine death","volume":"21","author":"E Krumb","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/trf.15308","article-title":"Plasma-derived factor\u2009X therapy for treatment of intracranial bleeding in a patient with factor\u2009X deficiency: a case report","volume":"59","author":"O Grottke","year":"2019","journal-title":"Transfusion"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"100833","DOI":"10.1016\/j.blre.2021.100833","article-title":"Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency","volume":"50","author":"F Peyvandi","year":"2021","journal-title":"Blood Rev"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.21207","article-title":"Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation","volume":"83","author":"A Girolami","year":"2008","journal-title":"Am J Hematol"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1073\/pnas.81.12.3699","article-title":"Characterization of a cDNA coding for human factor X","volume":"81","author":"S P Leytus","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"ref20","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1021\/bi00366a018","article-title":"Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C","volume":"25","author":"S P Leytus","year":"1986","journal-title":"Biochemistry"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/1873-3468.14321","article-title":"Site-specific functional roles of the factor X activation peptide in the intrinsic tenase-mediated factor X activation","volume":"596","author":"A Carnbring Bonde","year":"2022","journal-title":"FEBS Lett"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.V74.5.1486.1486","article-title":"Molecular characterization of human factor X San Antonio","volume":"74","author":"S V Reddy","year":"1989","journal-title":"Blood"},{"issue":"07","key":"ref23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0039-1687889","article-title":"Molecular diagnosis of inherited coagulation and bleeding disorders","volume":"45","author":"J M Bastida","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1055\/a-1704-0841","article-title":"Analysis of 180 genetic variants in a new interactive FX variant database reveals novel insights into FX deficiency","volume":"5","author":"V A Harris","year":"2021","journal-title":"TH Open"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0002-9343(99)80256-3","article-title":"Treatment of inherited coagulation disorders","volume":"99","author":"A J Cohen","year":"1995","journal-title":"Am J Med"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.tracli.2008.03.001","article-title":"The use of fresh frozen plasma (FFP) in 2007 in France","volume":"14","author":"D Benhamou","year":"2007","journal-title":"Transfus Clin Biol"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminhematol.2020.07.006","article-title":"Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease","volume":"57","author":"P M Nair","year":"2020","journal-title":"Semin Hematol"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/cc9311","article-title":"Clinical review: prothrombin complex concentrates\u2013evaluation of safety and thrombogenicity","volume":"15","author":"B S\u00f8rensen","year":"2011","journal-title":"Crit Care"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2516.2011.02635.x","article-title":"Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe factor X deficiency in Iran","volume":"18","author":"M Karimi","year":"2012","journal-title":"Haemophilia"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17425255.2016.1237504","article-title":"Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety","volume":"13","author":"A Shapiro","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hae.14894","article-title":"Plasma-derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency","volume":"30","author":"M A Escobar","year":"2024","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref34","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.thromres.2006.01.015","article-title":"Prophylaxis in rare coagulation disorders \u2013 factor X deficiency","volume":"118","author":"G Auerswald","year":"2006","journal-title":"Thromb Res"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/hae.14570","article-title":"A review of the pharmacokinetics, efficacy and safety of high-purity factor X for the prophylactic treatment of hereditary factor X deficiency","volume":"28","author":"J Payne","year":"2022","journal-title":"Haemophilia"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/hae.13729","article-title":"Congenital factor X deficiency in women: a systematic review of the literature","volume":"25","author":"D Spiliopoulos","year":"2019","journal-title":"Haemophilia"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/ph15101183","article-title":"Updates on novel non-replacement drugs for hemophilia","volume":"15","author":"R Gualtierotti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref38","first-page":"MP-219","article-title":"Thrombin generation response with the addition of bypassing agents in plasma of patients treated with fitusiran","volume":"24","author":"K Qian","year":"2018","journal-title":"Hemophilia"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.2023023404","article-title":"Fitusiran reduces bleeding in factor X-deficient mice","volume":"144","author":"S Verhenne","year":"2024","journal-title":"Blood"},{"issue":"S 01","key":"ref40","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2022-170245","article-title":"Pre-clinical characterization of VGA039, an anti-protein s monoclonal antibody being developed as a universal hemostatic agent for various bleeding disorders","volume":"140","author":"L Leong","year":"2022","journal-title":"Blood"},{"issue":"S 01","key":"ref41","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood-2018-99-119674","article-title":"The tissue factor pathway inhibitor antibody, PF-06741086, increases thrombin generation in rare bleeding disorder and von Willebrand factor deficient plasmas","volume":"132","author":"S Rakhe","year":"2018","journal-title":"Blood"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-0041-1722862","article-title":"Gene therapy for inherited bleeding disorders","volume":"47","author":"V R Arruda","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"S 02","key":"ref43","first-page":"e12589","article-title":"Evaluation of pharmacological enhancers of mutated factor VII activity ex vivo","volume":"5","author":"M Andresen","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thromres.2023.10.001","article-title":"Treatment of congenital coagulopathies, from biologic to biotechnological drugs: the relevance of gene editing (CRISPR\/Cas)","volume":"231","author":"J A De Pablo-Moreno","year":"2023","journal-title":"Thromb Res"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1789595.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:42:09Z","timestamp":1740008529000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1789595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":42,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,2,19]]},"published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1789595","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}